BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Age-related macular degeneration (ARMD) is the leading cause of severe vision loss in the developed world for people over 55 ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...

Opthea (ASX:OPT) has announced a boost to its cash reserves, receiving a $15.9m research and development tax incentive from ...

Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

A PD-1/VEGF bispecific antibody is a type of cancer drug designed to target both the programmed cell death protein 1, or PD-1, on immune cells and vascular endothelial growth factor, or VEGF, on tumor ...

in patients who failed therapy with drugs targeting vascular endothelial growth factor (VEGF). Sodhi and his colleagues ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...